The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.
Daniel Oscar Persky
No relevant relationships to disclose
Steven H. Bernstein
No relevant relationships to disclose
Bryan H. Goldman
No relevant relationships to disclose
Lisa M. Rimsza
No relevant relationships to disclose
Richard I. Fisher
No relevant relationships to disclose
Thomas P. Miller
Research Funding - Spectrum Pharmaceuticals